MedNet.nl: In combination with lazertinib, subcutaneous amivantamab is noninferior to intravenous amivantamab in terms of pharmacokinetics and objective response as treatment for advanced EGFR-mutated NSCLC. This is evident from the results of the PALOMA 3 study. Unexpectedly, these results also showed that duration of response, progression-free survival, and overall survival were longer in the subcutaneously treated arm, indicating that the route of administration may influence outcomes, according to the researchers.
03-06-2024 | NSCLC | News